HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007)

Figure 1

Antiviral activity of SRI-32007 against HBV genotype D in HepG2.2.2.15 cells. HepG2.2.2.15 cells in 96 wells were treated with different concentrations of SRI-32007 for six days followed by measurement of virus associated DNA in the culture supernatants by HBV specific qPCR. HBV DNA and HBe Ag levels in the treated samples and cell viability normalized to the untreated samples (average ± standard deviation from triplicate samples) are shown in the figure.